Glaukos Corporation (NYSE:GKOS) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 21.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 327,036 shares of the medical instruments supplier's stock after acquiring an additional 58,502 shares during the quarter. Principal Financial Group Inc. owned about 0.57% of Glaukos worth $32,187,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its position in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 158 shares during the period. Whipplewood Advisors LLC lifted its holdings in shares of Glaukos by 3,957.1% in the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 277 shares during the period. First Horizon Advisors Inc. increased its stake in Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after purchasing an additional 159 shares in the last quarter. Versant Capital Management Inc increased its stake in Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 327 shares in the last quarter. Finally, CoreCap Advisors LLC increased its stake in Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after purchasing an additional 200 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Price Performance

GKOS stock opened at $101.69 on Tuesday. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71. The stock's fifty day simple moving average is $96.00 and its 200-day simple moving average is $115.20. The company has a quick ratio of 5.62, a current ratio of 6.49 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $5.81 billion, a price-to-earnings ratio of -42.91 and a beta of 0.82.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. Glaukos had a negative return on equity of 10.66% and a negative net margin of 31.40%. The business had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. During the same quarter last year, the firm earned ($0.70) earnings per share. The business's revenue was up 24.6% on a year-over-year basis. Equities research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Wells Fargo & Company downgraded Glaukos from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $160.00 to $86.00 in a research note on Thursday, May 1st. Piper Sandler dropped their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, April 15th. Mizuho dropped their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Morgan Stanley dropped their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Needham & Company LLC dropped their price target on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $134.67.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.